Analyst consensus rating
Metagenomi Therapeutics Analyst Rating: Strong Buy
MGX is rated Strong Buy by 3 analysts with a $7.00 target. As of 2026-08-24.
Direct answer
Metagenomi Therapeutics's consensus rating is Strong Buy.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.00.
Forecast evidence checked August 24, 2026.
Get free Metagenomi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.21
- Average price target
- $7.00
- High price target
- $9.00
- Low price target
- $5.00
- Low target gap
- +313.2%
- Target upside
- +478.5%
- High target gap
- +643.8%
- Target range width
- 330.6%
- Consensus rating
- Strong Buy
- Analysts
- 3
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Metagenomi Therapeutics?
Metagenomi Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $7.00.
How far are Metagenomi Therapeutics's low and high targets from the recorded price?
The low target implies +313.2%, while the high target implies +643.8%.
How many analysts are included in Metagenomi Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Metagenomi Therapeutics's target upside or downside calculated?
The average target of $7.00 is divided by the recorded price of $1.21, then one is subtracted to produce +478.5%. This does not guarantee a future return.
When was Metagenomi Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.